{"id":56188,"date":"2023-04-25T14:05:21","date_gmt":"2023-04-25T12:05:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/"},"modified":"2023-04-25T14:05:21","modified_gmt":"2023-04-25T12:05:21","slug":"urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/","title":{"rendered":"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference"},"content":{"rendered":"
\n

\n– Fireside Chat May 2, 2023 from 10:00 \u2013 10:30 AM ET –<\/i><\/p>\n

PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the upcoming H.C. Wainwright BioConnect Conference on May 2, 2023 at 10:00 AM ET.<\/p>\n

<\/a><\/p>\n

\nA live audio webcast will be available in the “Events and Presentations<\/a>” section of UroGen\u2019s investor website. A replay will be available for approximately 30 days.<\/p>\n

\nAbout UroGen Pharma Ltd.<\/b><\/p>\n

\nUroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel\u00ae reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen\u2019s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto\u00ae (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com<\/a> to learn more or follow us on Twitter, @UroGenPharma.<\/p>\n

Contacts<\/b> <\/p>\n

\nINVESTOR CONTACT:<\/b>
Vincent Perrone
\n
Senior Director, Investor Relations
\n
vincent.perrone@urogen.com<\/a>
609-460-3588<\/p>\n

\nMEDIA CONTACT:<\/b>
Cindy Romano
\n
UroGen Corporate Communications
\n
cindy.romano@urogen.com<\/a>
908-963-7827<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

– Fireside Chat May 2, 2023 from 10:00 \u2013 10:30 AM ET – PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the upcoming H.C. Wainwright BioConnect Conference on May … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56188","6":"format-standard","7":"category-industry"},"yoast_head":"\nUroGen Pharma to Present at H.C. Wainwright BioConnect Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"– Fireside Chat May 2, 2023 from 10:00 \u2013 10:30 AM ET – PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the upcoming H.C. Wainwright BioConnect Conference on May ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T12:05:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230425005188\/en\/1772465\/21\/UroGen_logo2_%28R%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference\",\"datePublished\":\"2023-04-25T12:05:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/\"},\"wordCount\":244,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005188\\\/en\\\/1772465\\\/21\\\/UroGen_logo2_%28R%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/\",\"name\":\"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005188\\\/en\\\/1772465\\\/21\\\/UroGen_logo2_%28R%29.jpg\",\"datePublished\":\"2023-04-25T12:05:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005188\\\/en\\\/1772465\\\/21\\\/UroGen_logo2_%28R%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230425005188\\\/en\\\/1772465\\\/21\\\/UroGen_logo2_%28R%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/","og_locale":"en_US","og_type":"article","og_title":"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference - Pharma Trend","og_description":"– Fireside Chat May 2, 2023 from 10:00 \u2013 10:30 AM ET – PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the upcoming H.C. Wainwright BioConnect Conference on May ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-25T12:05:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230425005188\/en\/1772465\/21\/UroGen_logo2_%28R%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference","datePublished":"2023-04-25T12:05:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/"},"wordCount":244,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425005188\/en\/1772465\/21\/UroGen_logo2_%28R%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/","url":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/","name":"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230425005188\/en\/1772465\/21\/UroGen_logo2_%28R%29.jpg","datePublished":"2023-04-25T12:05:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230425005188\/en\/1772465\/21\/UroGen_logo2_%28R%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230425005188\/en\/1772465\/21\/UroGen_logo2_%28R%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/urogen-pharma-to-present-at-h-c-wainwright-bioconnect-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"UroGen Pharma to Present at H.C. Wainwright BioConnect Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56188"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56188\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}